ArticleFrontiers in oncology2021

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

Chul Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.